This stock has massive implied upside to the Stifel analysts target. Stonebridge Biopharma PLC (NASDAQ: SBBP) operates as a commercial-stage biopharmaceutical company that focuses on the development and commercialization of therapies for rare diseases. Its pipeline is comprised of Keveyis, Macrilen, Recorlev and Veldoreotide.
Last week the company presented new data analyses from the Phase 3 SONICS study of Recorlev for the potential treatment of endogenous Cushing’s syndrome. Improvements in hemoglobin A1c and fasting blood glucose in the maintenance phase were more pronounced among patients with comorbid diabetes mellitus, while antidiabetic medications were more often decreased than increased.
In addition, the clinicals showed significant improvements in cardiovascular risk markers of low-density lipoprotein (LDL)-cholesterol, weight, body mass index and waist circumference were seen in patients with and without diabetes mellitus. Additionally, improvement in LDL-cholesterol occurred without any new use of statins or increases in statin dose.
The massive $15 Stifel price target compares to a $14.29 consensus across Wall Street. The stock ended the week at $4.98 per share.
This stock has been blitzed over the last year and offers aggressive accounts a very timely entry point. Sientra Inc. (NASDAQ: SIEN) as a medical aesthetics company that engages in developing and commercializing plastic surgery implantable devices. It operates through two reportable segments.
The Breast Products segment focuses on sales of its breast implants, tissue expanders and scar management products under the brands Sientra, AlloX2, Dermaspan, Softspan and Biocorneum. The miraDry segment focuses on sales of the miraDry System, consisting of a console and a handheld device that uses consumable single-use bioTips.
With breast implants under scrutiny lately, the company told the FDA that the primary focus is upholding the highest levels of patient safety. Importantly, the totality of the firm’s clinical and real-world data, including its 10-year Post-Approval Cohort Study, which included almost 1,800 participants fully met FDA’s compliance requirements, and has confirmed the long-term safety and effectiveness of the company’s products.
Stifel has set its price target at $16. The higher consensus figure is $19.50, and shares were trading at $8.58 as the week came to a close.
This small-cap driller may provide some serious upside for energy accounts. W&T Offshore Inc. (NYSE: WTI) engages in the production, exploration, development and acquisition of oil and natural gas properties. Its operations are focused in the Gulf of Mexico.
Last week the company was the apparent high bidder on eight deepwater and seven shallow-water blocks, which includes Garden Banks 173; Green Canyon blocks 3, 46, 47, 49, 91 and 92; and Mississippi Canyon 244 in the deepwater, as well as Eugene Island blocks 357, 378, 393, 395, 396; Main Pass 286; and South Marsh 205 in the shallow water.
These 15 blocks cover approximately 73,500 acres and, if awarded, the company will pay approximately $3.5 million for all the awarded leases combined, which reflects a 100% working interest in the acreage. All the blocks have a five-year lease term, with the exception of one of the deepwater blocks, which has a seven-year lease term. The royalty rate for eight of the blocks is 12.5%, and the remaining seven leases are at a rate of 18.75%.
The Stifel team has a $10 price target. The consensus target is $7.25, and the shares were last seen at $6.90 apiece.
These are five stocks for aggressive accounts that look to get share count leverage on companies that have sizable upside potential. While not suited for all investors, these are not penny stocks with absolutely no track record or liquidity, and major Wall Street firms have research coverage on them all.